Livzon Pharmaceutical Group Inc. (HKG:1513)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
28.42
+0.22 (0.78%)
Apr 28, 2026, 4:08 PM HKT
6.44%
Market Cap 30.54B
Revenue (ttm) 13.31B
Net Income (ttm) 2.23B
Shares Out n/a
EPS (ttm) 2.51
PE Ratio 13.68
Forward PE 12.98
Dividend 1.20 (4.26%)
Ex-Dividend Date Jun 13, 2025
Volume 641,100
Average Volume 1,127,084
Open 28.20
Previous Close 28.20
Day's Range 28.04 - 28.56
52-Week Range 25.60 - 41.85
Beta 0.38
RSI 49.86
Earnings Date Apr 23, 2026

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neuro... [Read more]

Sector Healthcare
Founded 1985
Employees 8,878
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1513
Full Company Profile

Financial Performance

In 2025, HKG:1513's revenue was 12.02 billion, an increase of 1.76% compared to the previous year's 11.81 billion. Earnings were 2.02 billion, a decrease of -1.84%.

Financial numbers in CNY

News

There is no news available yet.